Aktieanalys

BioInvent: BI-1808 Shown to Be Safe as Monotherapy - Redeye

{newsItem.title}

Redeye Publicerad: 06 Sep 2022 09:56

Redeye comments on BioInvent’s completed dose escalation (part A) in the phase I/IIa trial of BI-1808 in advanced cancer.

Länk till analysen i sin helhet: https://www.redeye.se/research/854913/bioinvent-bi-1808-shown-to-be-safe-as-monotherapy?utm_source=finwire&utm_medium=RSS

Nyheter om Bioinvent

Läses av andra just nu

Om aktien Bioinvent

Senaste nytt